Cargando…

Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)

Although the antibody response induced by primary vaccination with Fel-O-Vax(®) FIV (three doses, 2–4 weeks apart) is well described, the antibody response induced by annual vaccination with Fel-O-Vax(®) FIV (single dose every 12 months after primary vaccination) and how it compares to the primary a...

Descripción completa

Detalles Bibliográficos
Autores principales: Westman, Mark, Yang, Dennis, Green, Jennifer, Norris, Jacqueline, Malik, Richard, Parr, Yasmin A., McDonald, Mike, Hosie, Margaret J., VandeWoude, Sue, Miller, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998844/
https://www.ncbi.nlm.nih.gov/pubmed/33809232
http://dx.doi.org/10.3390/v13030470
_version_ 1783670645774614528
author Westman, Mark
Yang, Dennis
Green, Jennifer
Norris, Jacqueline
Malik, Richard
Parr, Yasmin A.
McDonald, Mike
Hosie, Margaret J.
VandeWoude, Sue
Miller, Craig
author_facet Westman, Mark
Yang, Dennis
Green, Jennifer
Norris, Jacqueline
Malik, Richard
Parr, Yasmin A.
McDonald, Mike
Hosie, Margaret J.
VandeWoude, Sue
Miller, Craig
author_sort Westman, Mark
collection PubMed
description Although the antibody response induced by primary vaccination with Fel-O-Vax(®) FIV (three doses, 2–4 weeks apart) is well described, the antibody response induced by annual vaccination with Fel-O-Vax(®) FIV (single dose every 12 months after primary vaccination) and how it compares to the primary antibody response has not been studied. Residual blood samples from a primary FIV vaccination study (n = 11), and blood samples from cats given an annual FIV vaccination (n = 10), were utilized. Samples from all 21 cats were tested with a commercially available PCR assay (FIV RealPCR(TM)), an anti-p24 microsphere immunoassay (MIA), an anti-FIV transmembrane (TM; gp40) peptide ELISA, and a range of commercially available point-of-care (PoC) FIV antibody kits. PCR testing confirmed all 21 cats to be FIV-uninfected for the duration of this study. Results from MIA and ELISA testing showed that both vaccination regimes induced significant antibody responses against p24 and gp40, and both anti-p24 and anti-gp40 antibodies were variably present 12 months after FIV vaccination. The magnitude of the antibody response against both p24 and gp40 was significantly higher in the primary FIV vaccination group than in the annual FIV vaccination group. The differences in prime versus recall post-vaccinal antibody levels correlated with FIV PoC kit performance. Two FIV PoC kits that detect antibodies against gp40, namely Witness(®) and Anigen Rapid(®), showed 100% specificity in cats recently administered an annual FIV vaccination, demonstrating that they can be used to accurately distinguish vaccination and infection in annually vaccinated cats. A third FIV PoC kit, SNAP(®) Combo, had 0% specificity in annually FIV-vaccinated cats, and should not be used in any cat with a possible history of FIV vaccination. This study outlines the antibody response to inactivated Fel-O-Vax(®) FIV whole-virus vaccine, and demonstrates how best to diagnose FIV infection in jurisdictions where FIV vaccination is practiced.
format Online
Article
Text
id pubmed-7998844
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79988442021-03-28 Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV) Westman, Mark Yang, Dennis Green, Jennifer Norris, Jacqueline Malik, Richard Parr, Yasmin A. McDonald, Mike Hosie, Margaret J. VandeWoude, Sue Miller, Craig Viruses Article Although the antibody response induced by primary vaccination with Fel-O-Vax(®) FIV (three doses, 2–4 weeks apart) is well described, the antibody response induced by annual vaccination with Fel-O-Vax(®) FIV (single dose every 12 months after primary vaccination) and how it compares to the primary antibody response has not been studied. Residual blood samples from a primary FIV vaccination study (n = 11), and blood samples from cats given an annual FIV vaccination (n = 10), were utilized. Samples from all 21 cats were tested with a commercially available PCR assay (FIV RealPCR(TM)), an anti-p24 microsphere immunoassay (MIA), an anti-FIV transmembrane (TM; gp40) peptide ELISA, and a range of commercially available point-of-care (PoC) FIV antibody kits. PCR testing confirmed all 21 cats to be FIV-uninfected for the duration of this study. Results from MIA and ELISA testing showed that both vaccination regimes induced significant antibody responses against p24 and gp40, and both anti-p24 and anti-gp40 antibodies were variably present 12 months after FIV vaccination. The magnitude of the antibody response against both p24 and gp40 was significantly higher in the primary FIV vaccination group than in the annual FIV vaccination group. The differences in prime versus recall post-vaccinal antibody levels correlated with FIV PoC kit performance. Two FIV PoC kits that detect antibodies against gp40, namely Witness(®) and Anigen Rapid(®), showed 100% specificity in cats recently administered an annual FIV vaccination, demonstrating that they can be used to accurately distinguish vaccination and infection in annually vaccinated cats. A third FIV PoC kit, SNAP(®) Combo, had 0% specificity in annually FIV-vaccinated cats, and should not be used in any cat with a possible history of FIV vaccination. This study outlines the antibody response to inactivated Fel-O-Vax(®) FIV whole-virus vaccine, and demonstrates how best to diagnose FIV infection in jurisdictions where FIV vaccination is practiced. MDPI 2021-03-12 /pmc/articles/PMC7998844/ /pubmed/33809232 http://dx.doi.org/10.3390/v13030470 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Westman, Mark
Yang, Dennis
Green, Jennifer
Norris, Jacqueline
Malik, Richard
Parr, Yasmin A.
McDonald, Mike
Hosie, Margaret J.
VandeWoude, Sue
Miller, Craig
Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)
title Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)
title_full Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)
title_fullStr Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)
title_full_unstemmed Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)
title_short Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax(®) FIV)
title_sort antibody responses in cats following primary and annual vaccination against feline immunodeficiency virus (fiv) with an inactivated whole-virus vaccine (fel-o-vax(®) fiv)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998844/
https://www.ncbi.nlm.nih.gov/pubmed/33809232
http://dx.doi.org/10.3390/v13030470
work_keys_str_mv AT westmanmark antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT yangdennis antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT greenjennifer antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT norrisjacqueline antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT malikrichard antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT parryasmina antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT mcdonaldmike antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT hosiemargaretj antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT vandewoudesue antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv
AT millercraig antibodyresponsesincatsfollowingprimaryandannualvaccinationagainstfelineimmunodeficiencyvirusfivwithaninactivatedwholevirusvaccinefelovaxfiv